# Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

> **NCT03838367** · PHASE1,PHASE2 · TERMINATED · sponsor: **CytoDyn, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** 350 mg leronlimab
- **DRUG:** 525 mg leronlimab
- **DRUG:** 700 mg leronlimab
- **DRUG:** AUC 5 Carboplatin
- **DRUG:** Maximum Tolerated Dose (MTD) of leronlimab

## Key facts

- **NCT ID:** NCT03838367
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-22
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-09-16
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study terminated prematurely due to business reasons. Participants are no longer examined or receiving intervention.
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838367, "Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03838367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*